Technical Analysis for ANVS - Annovis Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 18.01 | 32.43% | 4.41 |
ANVS closed up 32.43 percent on Friday, April 26, 2024, on 4.15 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Parabolic Rise | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 14 hours ago |
| 2x Volume Pace | about 17 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
| Up 2 ATRs | about 17 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Alzheimer's Disease Parkinson's Disease Psychiatric Diagnosis Amyloid Nervous System Neurodegeneration Neurodegenerative Disorders Cognitive Disorders Cognitive Impairment Learning Disabilities Neuroprotection Early Stage Alzheimer's Disease Gladstone Institutes
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Alzheimer's Disease Parkinson's Disease Psychiatric Diagnosis Amyloid Nervous System Neurodegeneration Neurodegenerative Disorders Cognitive Disorders Cognitive Impairment Learning Disabilities Neuroprotection Early Stage Alzheimer's Disease Gladstone Institutes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.49 |
| 52 Week Low | 5.42 |
| Average Volume | 254,844 |
| 200-Day Moving Average | 10.70 |
| 50-Day Moving Average | 10.62 |
| 20-Day Moving Average | 11.64 |
| 10-Day Moving Average | 11.78 |
| Average True Range | 1.31 |
| RSI (14) | 78.35 |
| ADX | 28.39 |
| +DI | 49.56 |
| -DI | 12.66 |
| Chandelier Exit (Long, 3 ATRs) | 14.28 |
| Chandelier Exit (Short, 3 ATRs) | 12.78 |
| Upper Bollinger Bands | 15.18 |
| Lower Bollinger Band | 8.11 |
| Percent B (%b) | 1.4 |
| BandWidth | 60.79 |
| MACD Line | 0.88 |
| MACD Signal Line | 0.33 |
| MACD Histogram | 0.5488 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.75 | ||||
| Resistance 3 (R3) | 24.06 | 21.13 | 23.62 | ||
| Resistance 2 (R2) | 21.13 | 19.41 | 21.47 | 23.25 | |
| Resistance 1 (R1) | 19.57 | 18.36 | 20.35 | 20.26 | 22.87 |
| Pivot Point | 16.64 | 16.64 | 17.03 | 16.98 | 16.64 |
| Support 1 (S1) | 15.08 | 14.92 | 15.86 | 15.77 | 13.15 |
| Support 2 (S2) | 12.15 | 13.87 | 12.49 | 12.77 | |
| Support 3 (S3) | 10.59 | 12.15 | 12.40 | ||
| Support 4 (S4) | 11.28 |
